PL2794604T3 - Nowe dihydropirymidynoizochinolinony i zawierające je kompozycje farmaceutyczne do leczenia zaburzeń zapalnych - Google Patents

Nowe dihydropirymidynoizochinolinony i zawierające je kompozycje farmaceutyczne do leczenia zaburzeń zapalnych

Info

Publication number
PL2794604T3
PL2794604T3 PL12812237T PL12812237T PL2794604T3 PL 2794604 T3 PL2794604 T3 PL 2794604T3 PL 12812237 T PL12812237 T PL 12812237T PL 12812237 T PL12812237 T PL 12812237T PL 2794604 T3 PL2794604 T3 PL 2794604T3
Authority
PL
Poland
Prior art keywords
treatment
pharmaceutical compositions
inflammatory disorders
dihydropyrimidinoisoquinolinones
novel
Prior art date
Application number
PL12812237T
Other languages
English (en)
Inventor
Frédéric Gilbert Labéguère
Gregory John Robert Newsome
Luke Jonathan Alvey
Laurent Raymond Maurice Sanière
Stephen Robert Fletcher
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of PL2794604T3 publication Critical patent/PL2794604T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL12812237T 2011-12-22 2012-12-20 Nowe dihydropirymidynoizochinolinony i zawierające je kompozycje farmaceutyczne do leczenia zaburzeń zapalnych PL2794604T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161578979P 2011-12-22 2011-12-22
PCT/EP2012/076275 WO2013092791A1 (en) 2011-12-22 2012-12-20 Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP12812237.1A EP2794604B1 (en) 2011-12-22 2012-12-20 Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
PL2794604T3 true PL2794604T3 (pl) 2017-12-29

Family

ID=47520068

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17184834T PL3378862T3 (pl) 2011-12-22 2012-12-20 Dihydropirymidynoizochinolinony i ich kompozycie farmaceutyczne do leczenia stwardnienia rozsianego
PL12812237T PL2794604T3 (pl) 2011-12-22 2012-12-20 Nowe dihydropirymidynoizochinolinony i zawierające je kompozycje farmaceutyczne do leczenia zaburzeń zapalnych

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL17184834T PL3378862T3 (pl) 2011-12-22 2012-12-20 Dihydropirymidynoizochinolinony i ich kompozycie farmaceutyczne do leczenia stwardnienia rozsianego

Country Status (35)

Country Link
US (5) US8927543B2 (pl)
EP (3) EP4019519A1 (pl)
JP (1) JP6062453B2 (pl)
KR (1) KR102012268B1 (pl)
CN (1) CN103998448B (pl)
AR (1) AR089284A1 (pl)
AU (1) AU2012357067B2 (pl)
BR (1) BR112014015142B1 (pl)
CA (1) CA2859578C (pl)
CL (1) CL2014001664A1 (pl)
CO (1) CO7010835A2 (pl)
CR (1) CR20140305A (pl)
CY (1) CY1119434T1 (pl)
DK (2) DK3378862T3 (pl)
EA (1) EA023826B1 (pl)
ES (2) ES2643379T3 (pl)
HK (1) HK1201528A1 (pl)
HR (2) HRP20220456T1 (pl)
HU (1) HUE12812237T4 (pl)
IL (2) IL233212B (pl)
IN (1) IN2014MN01033A (pl)
LT (2) LT2794604T (pl)
MX (1) MX351681B (pl)
NI (1) NI201400060A (pl)
PE (1) PE20141685A1 (pl)
PH (1) PH12014501178A1 (pl)
PL (2) PL3378862T3 (pl)
PT (2) PT2794604T (pl)
SG (1) SG11201403169PA (pl)
SI (2) SI3378862T1 (pl)
TW (1) TWI567073B (pl)
UA (1) UA111767C2 (pl)
UY (1) UY34545A (pl)
WO (1) WO2013092791A1 (pl)
ZA (1) ZA201404607B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2794627B1 (en) 2011-12-22 2018-09-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2935262B1 (en) * 2012-12-20 2017-03-15 Galapagos NV Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)
GB201319677D0 (en) * 2013-11-07 2013-12-25 Eth Z Rich Cyclopropanation
GB201411241D0 (en) * 2014-06-25 2014-08-06 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201506894D0 (en) * 2015-04-23 2015-06-10 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
KR102305710B1 (ko) * 2017-03-06 2021-09-30 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 Gpr84 수용체 길항제 및 이의 용도
EP3403649A1 (en) 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitors and antagonists of gpr84 for the treatment of endometriosis
EP3710004A1 (en) * 2017-11-15 2020-09-23 Galapagos NV Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
TW202136271A (zh) 2019-12-19 2021-10-01 德商拜耳廠股份有限公司 呋喃并吲唑衍生物
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
US20230405007A1 (en) 2020-11-24 2023-12-21 Galapagos Nv Compound for use in and methods of treatment of fibrotic diseases
WO2022179940A1 (en) * 2021-02-23 2022-09-01 Bayer Aktiengesellschaft Furoindazole derivatives as gpr84 antagonists
CN115109072A (zh) * 2021-03-18 2022-09-27 武汉人福创新药物研发中心有限公司 一种gpr84拮抗剂及其制备方法和用途
WO2022218372A1 (zh) * 2021-04-14 2022-10-20 武汉人福创新药物研发中心有限公司 一种二氢嘧啶并异喹啉酮类衍生物及用途
EP4330260A1 (en) 2021-04-29 2024-03-06 Bayer Aktiengesellschaft Furoindazole derivatives as antagonists or inhibitors of gpr84
EP4355743A1 (en) 2021-06-18 2024-04-24 University of Copenhagen Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
EP4361151A1 (en) * 2021-06-21 2024-05-01 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Tricyclic compound used as gpr84 antagonist
CN115611944A (zh) 2021-07-15 2023-01-17 中国科学院上海药物研究所 不对称gpr84拮抗剂及其用途
WO2023076668A1 (en) * 2021-10-29 2023-05-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions and methods for treatment of cancer
WO2024083705A1 (en) 2022-10-18 2024-04-25 Bayer Aktiengesellschaft Furoindazole derivatives for the treatment of pain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2720085A1 (de) 1977-05-05 1978-11-16 Hoechst Ag Pyrimido(6,1-a)isochinolin-2-on- derivate
ES2253821T3 (es) * 1997-07-12 2006-06-01 Cancer Research Technology Limited Derivados de purina inhibidores de quinasa que depende de ciclina.
WO2000058309A1 (en) * 1999-03-31 2000-10-05 Vernalis Limited Derivatives of pyrimido[6,1-a]isoquinolin-4-one
JP2007525475A (ja) * 2003-07-08 2007-09-06 スミスクライン・ビーチャム・コーポレイション 新規化学化合物
WO2005050225A2 (en) 2003-10-31 2005-06-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
EP1929310A2 (en) * 2005-09-02 2008-06-11 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
AR073354A1 (es) 2008-07-31 2010-11-03 Genentech Inc Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer.
JP2011088847A (ja) * 2009-10-21 2011-05-06 Takeda Chem Ind Ltd 三環性化合物およびその用途
AU2012372019B2 (en) 2011-12-22 2017-06-15 Connexios Life Sciences Pvt. Ltd. Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof
SG11201403266RA (en) 2011-12-22 2014-07-30 Connexios Life Sciences Pvt Ltd Derivatives of aza adamantane and uses thereof
PL2794600T3 (pl) 2011-12-22 2018-06-29 Novartis Ag Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
AR089284A1 (es) 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
EP2935262B1 (en) 2012-12-20 2017-03-15 Galapagos NV Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)

Also Published As

Publication number Publication date
DK2794604T3 (da) 2017-11-06
UY34545A (es) 2013-07-31
BR112014015142A2 (pt) 2017-06-13
JP2015500861A (ja) 2015-01-08
CR20140305A (es) 2014-07-23
HK1201528A1 (en) 2015-09-04
AU2012357067A1 (en) 2014-07-10
SG11201403169PA (en) 2014-07-30
NZ626473A (en) 2016-03-31
KR102012268B1 (ko) 2019-08-21
AU2012357067B2 (en) 2017-01-05
US8927543B2 (en) 2015-01-06
US20140121204A1 (en) 2014-05-01
HUE12812237T4 (hu) 2017-12-28
CO7010835A2 (es) 2014-07-31
EP3378862B1 (en) 2022-03-16
EA023826B1 (ru) 2016-07-29
CA2859578A1 (en) 2013-06-27
LT3378862T (lt) 2022-04-25
US20160244442A1 (en) 2016-08-25
ZA201404607B (en) 2020-02-26
PT2794604T (pt) 2017-10-23
ES2643379T9 (es) 2018-01-05
IN2014MN01033A (pl) 2015-05-01
EA201491245A1 (ru) 2014-10-30
ES2643379T3 (es) 2017-11-22
PE20141685A1 (es) 2014-11-25
US20220227751A1 (en) 2022-07-21
HRP20171404T1 (hr) 2017-11-17
SI3378862T1 (sl) 2022-05-31
MX2014007363A (es) 2014-08-01
EP2794604A1 (en) 2014-10-29
IL233212A0 (en) 2014-08-31
US10047083B2 (en) 2018-08-14
US20130165437A1 (en) 2013-06-27
LT2794604T (lt) 2017-10-25
WO2013092791A1 (en) 2013-06-27
DK3378862T3 (da) 2022-04-11
CN103998448A (zh) 2014-08-20
PH12014501178B1 (en) 2014-10-20
PT3378862T (pt) 2022-04-11
US11220499B2 (en) 2022-01-11
TW201331201A (zh) 2013-08-01
IL257581A (en) 2018-04-30
PL3378862T3 (pl) 2022-05-16
CL2014001664A1 (es) 2014-10-03
IL233212B (en) 2018-03-29
CN103998448B (zh) 2016-04-20
TWI567073B (zh) 2017-01-21
AR089284A1 (es) 2014-08-13
SI2794604T1 (sl) 2017-12-29
EP3378862A1 (en) 2018-09-26
CY1119434T1 (el) 2018-03-07
CA2859578C (en) 2020-03-10
EP4019519A1 (en) 2022-06-29
JP6062453B2 (ja) 2017-01-18
US20190002458A1 (en) 2019-01-03
NI201400060A (es) 2015-04-27
KR20140117427A (ko) 2014-10-07
ES2911449T3 (es) 2022-05-19
MX351681B (es) 2017-10-25
HRP20220456T1 (hr) 2022-05-27
BR112014015142B1 (pt) 2022-03-29
US9255095B2 (en) 2016-02-09
UA111767C2 (uk) 2016-06-10
EP2794604B1 (en) 2017-09-13
PH12014501178A1 (en) 2014-10-20

Similar Documents

Publication Publication Date Title
IL257581A (en) New dihydropyrimidineisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
HK1249507A1 (zh) 用於治療炎性障礙的新化合物及其藥物組合物
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
EP2552433A4 (en) COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES
HK1198909A1 (en) Compositions and methods for the treatment of hepatic diseases and disorders
HK1197235A1 (zh) 二氫吡唑、其藥物組合物及其治療生育障礙的用途
EP2675275A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS
HK1207293A1 (en) Composition for the treatment of inflammatory and immune disorders
ZA201408045B (en) Compositions and methods for the treatment of inflammation and lipid disorders
EP2767286A4 (de) Orale pharmazeutische zusammensetzung zur behandlung von entzündlichen magen-darm-erkrankungen